Dr. Lucia Sobrin is a full-time clinician scientist with Mass Eye and Ear's Retina and Uveitis Services. She has unique expertise diagnosing and treating rare and complicated eye disorders that affect the middle (uvea) and back (retina) portions of the eye. She has a specific clinical interest in the diagnosis and treatment of autoimmune retinopathy and cancer-associated retinopathy.  She also serves as Associate Director of the Retina Service and Director of the Morse Laser Center.

After obtaining her medical degree from the University Miami School of Medicine, Dr. Sobrin completed her ophthalmology residency training at Bascom Palmer Eye Institute. She then completed a medical and surgical retina fellowship at Mass Eye and Ear followed by a uveitis and ocular immunology fellowship at the Massachusetts Eye Research and Surgery Institute. In 2006, she became one of the Department's first Harvard Vision Clinical Scientist Research Program (K12) recipients and later received her Master of Public Health Degree from the Harvard School of Public Health.

In research, Dr. Sobrin is particularly interested in elucidating the genetics of diabetic retinopathy. As a Department of Ophthalmology Scholar, she led a candidate gene association study of diabetic retinopathy within the Candidate gene Association Resource (CARe), which included patients from several large population-based cohorts and an admixture genetic association study for diabetic retinopathy in African Americans. She currently leads a multi-ethnic genome-wide association study of diabetic retinopathy. In 2011, she was honored with the ARVO/Alcon Early Career Clinician Scientist Research Award. In 2015 she was honored with the Alcon Research Institute Young Investigator Award.

Dr. Sobrin shares her in-depth knowledge of rare and complex cases with uveitis and retina fellows as well as ophthalmology residents. She also co-directs Mass Eye and Ear's Uveitis Fellowship Program.

Clinical Interests

Retina, uveitis, diabetic retinopathy, autoimmune retinopathy, cancer-associated retinopathy